Track topics on Twitter Track topics that are important to you
SAINT-LAURENT, CANADA -- (Marketwired) -- 08/02/16 -- IntelGenx Technologies Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that it will release its second quarter 2016 results for the period ended June 30, 2016, on August 11, 2016 at the close of the financial markets.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Date: Thursday, August 11, 2016
Time: 4:30 p.m. ET
Conference dial-in: (877) 201-0168
Conference ID: 47950179
International dial-in: (647) 788-4901
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".
IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies.
Established in 2003, the Montreal-based company, listed on the TSX-V and OTC-QX, develops innovative oral drug delivery solutions based on its proprietary platform technologies, VersaFilm, VersaTab and AdVersa.
IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle management opportunities. Forfivo XL, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.Contacts: Edward Miller Director, IR and Corporate Communications IntelGenx Corp. +1 514-331-7440 (ext. 217) NEXT ARTICLE
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals. <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...